According to a recent article in the Pharma Times, E02463 is a therapy for indolent or slow growing, not yet problematic non-Hodgkin B cell lymphoma (iNHL). Enterome, its developer, has recently announced the initial results from its phase 1/2 EO2463 trial at the ICML conference demonstrating that EO2463 either as monotherapy or combined with standard of care has proven that it is well tolerated.
EO2463 was administered over a six-week period as a monotherapy. A 50% response rate was reached when the candidate was combined with rituximab and lenalidomide.
E02463 is an off-the-shelf treatment combining four synthetic OncoMimic peptides which have proven to be an excellent form of molecule to mimic protein sites. These peptides can be created as exact copies of protein fragments. The rationale for targeting these cell markers is to cause the full reduction of malignant B lymphocytes found in iNHL.
About E02463 Initial Data
Jan Fagerberg, M.D., CMO of Enterome, which is based in Paris, France stated that the data were encouraging and that E02463 was created as an expansion of pre-existing cytotoxic T cells (CTC). Memory CTC refers to the small number of CTC that remain in the body after the contraction phase. In that phase, 95% of iNH B-Cell Lymphomas are reduced.
Dr. Fagerberg added that he and his associates are encouraged that the candidate shows a promising safety profile confirming the company’s approach to OncoMimics immunotherapies that target liquid tumors.
OncoMimics are peptides originating from bacteria in the gut microbiome. These peptides mimic overexpressed tumor antigens or lineage markers in solid or liquid tumors respectfully.
2463 targets B cell markers and causes the destruction of malignant B lymphocytes found in abundance in iNHL.
Enterome is a biopharmaceutical company that develops novel drugs in accordance with its ability to de-code molecular interactions. The company’s success thus far is the result of its ability to seek out small proteins and peptides that deliver therapeutic benefits in humans.